Boosting bioavailability to topotecan: What do we gain?

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 177-

  Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

BIOAVAILABILITY; HUMAN; NOTE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; HUMANS; TOPOTECAN;

EID: 18844473220     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.21.1.177     Document Type: Letter

References (7)

1. Hudes G: Boosting bioavailability of topotecan: What do we gain? (Editorial). J Clin Oncol 20:2918-2919, 2002
2. O'Leary J, Muggia FM: Camptothecins: A review of their development and schedules of administration. Eur J Cancer 34:1500-1508, 1998
3. Miller DS, Blessing JA, Lentz SS, et al: Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol 84:507, 2002 (abstr 49)
4. Hoskins P, Eisenhauer E, Beare S, et al: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16:2233-2237, 1998
5. Chachoua A, Hochster H, Steinfeld A, et al: Feasibility of seven weeks concomitant topotecan continuous infusion with thoracic radiation. Proc Am Soc Clin Oncol 18:1684a, 1999 (abstr 1873)
6. Speyer J, Hochster H, Runowicz C, et al: First line therapy of ovarian cancer with cisplatin and prolonged infusion topotecan. Proc Am Soc Clin Oncol 17:350a, 1998 (abstr 1352)
7. Lilenbaum RC, Miller AA, Batist G, et al: Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: A Cancer and Leukemia Group B study. J Clin Oncol 16:3302-3309, 1998